Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Silicone breast implants seemed headed for museum shelves as failed relics of the American culture’s obsession with cosmetic surgery after thousands of lawsuits took them off the market in 1992, driving one manufacturer into bankruptcy. But Inamed Corp., a Santa Barbara medical products company that has sold the implants in 60 countries worldwide for years, is trying to bring them back to America. An expert panel of the Food and Drug Administration approved Inamed’s request in October, but the agency deferred a final decision on Jan. 8, citing a need for more information about the implants’ safety and failure rate. Yet it appears likely that Inamed will eventually get the green light, which raises the question: Why plunge into the shark-infested legal waters that in 1994 forced Dow Corning Inc., the nation’s largest implant manufacturer, out of the business? The reason, plaintiffs lawyers and defense attorneys say, is that science is on Inamed’s side. Recent studies favor breast implant manufacturers, they contend, and warning labels that didn’t exist a decade ago greatly reduce liability. “There’s an awful lot of science in the last 10 years that supports the safety of silicone as an implantable product,” says Gordon & Rees partner Jack “Skip” McCowan Jr., who has represented Dow Corning in several different proceedings. “There is no association between silicone and any auto-immune disease,” he says. “Any company coming into the market would have the benefit of that science.” Hersh & Hersh partner Nancy Hersh disagrees about implant safety, pointing out that most studies have been paid for and promoted by manufacturers. “I don’t believe those studies,” she says. “I’ve seen too many people who had the same injuries.” Nevertheless, Hersh, who represented many women in suits against implant manufacturers, agrees that the mass litigation seen in the ’90s isn’t likely to occur again. Silicone breast implants were first developed in the early 1960s for breast augmentation and reconstruction, with Texas native Timmie Jean Lindsey becoming the first recipient in 1962. A Houston attorney won the first suit against a manufacturer in 1977, but litigation didn’t spread until 1984, when San Francisco lawyer Daniel Bolton, then with the Hersh firm, obtained a $1.5 million judgment for a Nevada woman. Bolton followed up as a solo practitioner in 1991 with a historic $7.3 million judgment based on the theory that leaking silicone causes connective tissue disorders, leading to problems such as joint pain, rashes, dry mouth and eyes and chronic fatigue. A year later, the FDA requested a moratorium on new implants and manufacturers complied. An alternative — saline implants — is still available in the U.S., though they are considered less desirable than silicone. Dow Corning, which declared bankruptcy in 1994, eventually reached a $3.2 billion global settlement with more than 300,000 plaintiffs, but no money has been doled out to date. McCowan said he doesn’t believe Dow Corning has plans to get back into the business. “Claimants are anxiously awaiting payment on a plan they overwhelmingly voted approval for several years ago,” says Elizabeth Cabraser, a partner at Lieff, Cabraser, Heimann & Bernstein, which was a leader in the suits against manufacturers. Inamed officials didn’t respond to several calls and e-mails asking why they want to produce silicone implants for American use, or whether they anticipate heavy litigation. But defense lawyers say the company must have read the tea leaves and sees no problems. “My guess,” Sedgwick, Detert, Moran & Arnold partner Kevin Dunne says, “is they’ve done very careful analysis to look at the science in terms of causation and in the design of the product, and they feel like they’ve come up with a product that reduces the risks of side effects.” Dunne, who has defended several implant manufacturers, including Bristol-Myers Squibb Co., reiterates that if there are warnings on the product, “there is no basis for a lawsuit.” At worst, he says, a manufacturer could be sued for an individual defect if an implant has a weak spot that ruptures. Cabraser predicts that’s likely to happen, noting that silicone implants have a rupture rate of up to 90 percent over 10 years. “They break early and often,” she says. “They are simply not well designed to survive intact within the human body for more than a few years.” Cabraser also points out, however, that despite the possibility of ruptures causing permanent scarring and disfigurement — “an ironic outcome given the cosmetic goals of implantation” — demand by women remains high. And that could further insulate manufacturers. “Companies, attuned to this demand and the profit potential, may be willing to bear the risks of future litigation if new-generation implants prove as defective as their predecessors,” she says. Cabraser insists that manufacturers “lucked out,” arguing that women’s problems weren’t properly studied. “This should have made implant manufacturers more cautious, not less, in research and development of the product,” she says. “As it was, nearly a million women became guinea pigs in the breast implant experiment, and well over one-third of them have made disease, rupture or injury claims.” McCowan says it’s sour grapes. “That’s sort of a very typical response you get from plaintiffs lawyers when the science developed by honest and ethical scientists doesn’t support their position in a lawsuit,” he says. “Scientists go to great lengths to ensure they are not biased in their science, in their findings and in the protocols they develop for their studies.” McCowan also warned any plaintiffs lawyers against initiating a new legal war on silicone implants, noting the “latter history of the breast implant litigation — which was defense victory after defense victory. “The science,” he says, “caught up with the plaintiffs lawyers.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.